{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T14:50:20Z","timestamp":1780671020284,"version":"3.54.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T00:00:00Z","timestamp":1696204800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T00:00:00Z","timestamp":1696204800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS J"],"DOI":"10.1208\/s12248-023-00858-7","type":"journal-article","created":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T22:01:28Z","timestamp":1696284088000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["An Antibody-Dependent Cellular Cytotoxicity Assay for Detecting Ocrelizumab Neutralizing Antibody"],"prefix":"10.1208","volume":"25","author":[{"given":"Van","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Hendricks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,2]]},"reference":[{"key":"858_CR1","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/b978-0-444-52001-2.00010-8","volume":"122","author":"DS Goodin","year":"2014","unstructured":"Goodin DS. The epidemiology of multiple sclerosis: insights to disease pathogenesis. Handb Clin Neurol. 2014;122:231\u201366. https:\/\/doi.org\/10.1016\/b978-0-444-52001-2.00010-8.","journal-title":"Handb Clin Neurol"},{"issue":"3\u20134","key":"858_CR2","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1159\/000377675","volume":"73","author":"HC von B\u00fcdingen","year":"2015","unstructured":"von B\u00fcdingen HC, Palanichamy A, Lehmann-Horn K, Michel BA, Zamvil SS. Update on the autoimmune pathology of multiple sclerosis: B-cells as disease-drivers and therapeutic targets. Eur Neurol. 2015;73(3\u20134):238\u201346. https:\/\/doi.org\/10.1159\/000377675.","journal-title":"Eur Neurol"},{"issue":"7","key":"858_CR3","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1517\/14712590903018837","volume":"9","author":"F Kausar","year":"2009","unstructured":"Kausar F, Mustafa K, Sweis G, Sawaqed R, Alawneh K, Salloum R, et al. Ocrelizumab: a step forward in the evolution of B-cell therapy. Expert Opin Biol Ther. 2009;9(7):889\u201395. https:\/\/doi.org\/10.1517\/14712590903018837.","journal-title":"Expert Opin Biol Ther"},{"issue":"2","key":"858_CR4","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1053\/j.seminhematol.2010.01.007","volume":"47","author":"T van Meerten","year":"2010","unstructured":"van Meerten T, Hagenbeek A. CD20-targeted therapy: the next generation of antibodies. Semin Hematol. 2010;47(2):199\u2013210. https:\/\/doi.org\/10.1053\/j.seminhematol.2010.01.007.","journal-title":"Semin Hematol"},{"issue":"12\u201313","key":"858_CR5","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1016\/j.molimm.2011.04.010","volume":"48","author":"A Schnueriger","year":"2011","unstructured":"Schnueriger A, Grau R, Sondermann P, Schreitmueller T, Marti S, Zocher M. Development of a quantitative, cell-line based assay to measure ADCC activity mediated by therapeutic antibodies. Mol Immunol. 2011;48(12\u201313):1512\u20137. https:\/\/doi.org\/10.1016\/j.molimm.2011.04.010.","journal-title":"Mol Immunol"},{"key":"858_CR6","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.jim.2014.07.010","volume":"414","author":"ZJ Cheng","year":"2014","unstructured":"Cheng ZJ, Garvin D, Paguio A, Moravec R, Engel L, Fan F, et al. Development of a robust reporter-based ADCC assay with frozen, thaw-and-use cells to measure Fc effector function of therapeutic antibodies. J Immunol Methods. 2014;414:69\u201381. https:\/\/doi.org\/10.1016\/j.jim.2014.07.010.","journal-title":"J Immunol Methods"},{"issue":"6","key":"858_CR7","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1208\/s12248-015-9798-5","volume":"17","author":"Y Wu","year":"2015","unstructured":"Wu Y, Li JJ, Kim HJ, Liu X, Liu W, Akhgar A, et al. A neutralizing antibody assay based on a reporter of antibody-dependent cell-mediated cytotoxicity. AAPS J. 2015;17(6):1417\u201326. https:\/\/doi.org\/10.1208\/s12248-015-9798-5.","journal-title":"AAPS J"},{"key":"858_CR8","doi-asserted-by":"publisher","first-page":"19772","DOI":"10.1038\/srep19772","volume":"6","author":"M Yamashita","year":"2016","unstructured":"Yamashita M, Kitano S, Aikawa H, Kuchiba A, Hayashi M, Yamamoto N, et al. A novel method for evaluating antibody-dependent cell-mediated cytotoxicity by flowcytometry using cryopreserved human peripheral blood mononuclear cells. Sci Rep. 2016;6:19772. https:\/\/doi.org\/10.1038\/srep19772.","journal-title":"Sci Rep"},{"key":"858_CR9","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.jim.2017.04.005","volume":"447","author":"S Chung","year":"2017","unstructured":"Chung S, Nguyen V, Lin YL, Kamen L, Song A. Thaw-and-use target cells pre-labeled with calcein AM for antibody-dependent cell-mediated cytotoxicity assays. J Immunol Methods. 2017;447:37\u201346. https:\/\/doi.org\/10.1016\/j.jim.2017.04.005.","journal-title":"J Immunol Methods"},{"key":"858_CR10","doi-asserted-by":"publisher","unstructured":"Pharmacopeia US. Immunogenicity assays\u2014design and validation of assays to detect anti-drug neutralizing antibody. 2023;General Chapter(1106.1). https:\/\/doi.org\/10.31003\/USPNF_M8546_01_01.","DOI":"10.31003\/USPNF_M8546_01_01"},{"issue":"1\u20132","key":"858_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jim.2006.12.004","volume":"321","author":"S Gupta","year":"2007","unstructured":"Gupta S, Indelicato SR, Jethwa V, Kawabata T, Kelley M, Mire-Sluis AR, et al. Recommendations for the design, optimization, and qualification of cell-based assays used for the detection of neutralizing antibody responses elicited to biological therapeutics. J Immunol Methods. 2007;321(1\u20132):1\u201318. https:\/\/doi.org\/10.1016\/j.jim.2006.12.004.","journal-title":"J Immunol Methods"},{"issue":"6","key":"858_CR12","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1208\/s12248-016-9954-6","volume":"18","author":"B Wu","year":"2016","unstructured":"Wu B, Chung S, Jiang XR, McNally J, Pedras-Vasconcelos J, Pillutla R, et al. Strategies to determine assay format for the assessment of neutralizing antibody responses to biotherapeutics. Aaps j. 2016;18(6):1335\u201350. https:\/\/doi.org\/10.1208\/s12248-016-9954-6.","journal-title":"Aaps j"},{"key":"858_CR13","unstructured":"Guideline on Immunogenicity assessment of therapeutic proteins. EMEA\/CHMP\/BMWP\/14327\/2006 Rev 1 ed: European Medicines Agency; 2017."},{"key":"858_CR14","unstructured":"Immunogenicity testing of therapeutic protein products \u2014developing and validating assays for anti-drug antibody detection. In: U.S. Department of Health and Human Services FDA, editor. 2019."},{"key":"858_CR15","unstructured":"Horowitz D. Draft guidance for industry on assay development for immunogenicity testing of therapeutic proteins. In: Services DoHaH, editor. Federal Register 2009. p. 63758."},{"issue":"5","key":"858_CR16","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/j.jpba.2011.03.038","volume":"55","author":"S Gupta","year":"2011","unstructured":"Gupta S, Devanarayan V, Finco D, Gunn GR 3rd, Kirshner S, Richards S, et al. Recommendations for the validation of cell-based assays used for the detection of neutralizing antibody immune responses elicited against biological therapeutics. J Pharm Biomed Anal. 2011;55(5):878\u201388. https:\/\/doi.org\/10.1016\/j.jpba.2011.03.038.","journal-title":"J Pharm Biomed Anal"},{"key":"858_CR17","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s41120-021-00039-w","volume":"7","author":"T Zhang","year":"2021","unstructured":"Zhang T, Chen H, Shao W, Lin Z, Melhem M, Lu S, et al. A competitive ligand-binding assay for the detection of neutralizing antibodies against dostarlimab (TSR-042). AAPS Open. 2021;7:8. https:\/\/doi.org\/10.1186\/s41120-021-00039-w.","journal-title":"AAPS Open"},{"issue":"22","key":"858_CR18","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.4155\/bio-2021-0177","volume":"13","author":"V Ablamunits","year":"2021","unstructured":"Ablamunits V, Basak S, Henderson R, Caiazzo T, Kamerud J, et al. A competitive ligand-binding assay to detect neutralizing antibodies to a bispecific drug using a multiplex Meso Scale Discovery platform. Bioanalysis. 2021;13(22):1659\u201369. https:\/\/doi.org\/10.4155\/bio-2021-0177.","journal-title":"Bioanalysis"}],"container-title":["The AAPS Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-023-00858-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12248-023-00858-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-023-00858-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T18:12:41Z","timestamp":1700590361000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12248-023-00858-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,2]]},"references-count":18,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,11]]}},"alternative-id":["858"],"URL":"https:\/\/doi.org\/10.1208\/s12248-023-00858-7","relation":{},"ISSN":["1550-7416"],"issn-type":[{"value":"1550-7416","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,2]]},"assertion":[{"value":"27 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors are employees, past employees, and stockholders of Genentech, Inc. and F. Hoffmann-La Roche Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}],"article-number":"97"}}